Company & Sponsor Intelligence
UCB Pharma GmbH
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed3
Countries2
Therapeutic footprint
epilepsyparkinsons
Indexed studies
NCT01673282Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy
epilepsy · AustriaCOMPLETED
epilepsy · AustriaCOMPLETED
NCT01606670Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
parkinsons · AustriaCOMPLETED
parkinsons · AustriaCOMPLETED
NCT01098162Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
epilepsy · GermanyCOMPLETED
epilepsy · GermanyCOMPLETED
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →